Arctur part of €6 million international research project on real-time decision support in cancer surgery
The project is led by Ronan Cahill, Professor of Surgery at University College Dublin (UCD) and the Mater Misericordiae University Hospital, Dublin. Clinical validation of the technology will take place across five leading European cancer centers. CLASSICA builds on breakthrough research by the Irish DTIF Consortium comprising UCD, RCSI and IBM Research over the last three years at the Mater Hospital regarding the use of special dyes and AI to improve outcomes in cancer surgery.
The AI-based technology will assist surgeons in real-time during operations by accurately identifying cancerous versus healthy tissue. During the operation, a smart camera captures the color changes in tissue after the administration of a safe fluorescent dye. Video is processed by the AI, helping the surgeon to define excision extent. This added support, combined with the surgeon’s judgment and expertise, will minimise post-surgery complications and reduce the risk of cancer recurrence in the patient.
Having developed analytics software, smart cameras and surgical tools as well as trials and technology know-how immersed in real-world clinical care at the Mater, this new project will move the technology to the next stage of refinement, validation and use, as well as define the development of clinical guidelines related to AI use in surgery. Eleven partners from nine countries are joining forces to clinically validate this exciting AI technology. Alongside the UCD-Mater surgical team, there are four other clinical sites; Amsterdam UMC, location Stichting VUmc, Netherlands; Ziekenhuis Oost-Limburg (ZOL) Hospital, Belgium; University of Turin, Italy; and St John of God Hospital Graz, Austria. The team also includes IRCAD in Strasbourg, Europe’s leading surgical education organisation and the European Association of Endoscopic Surgery (EAES). Legal and ethical expertise is provided by Copenhagen University, Denmark and Pennsylvania State University, USA. Arctur contributes advanced AI and high-performance computing. Dublin-based Pintail Ltd will provide project management and administrative support throughout.
Clinical trials over the next four years will include 500 patients, with the technology initially being used for colorectal surgeries. Colorectal cancer is the third most common cancer type globally, and the second most common cause of cancer death, leading to almost one million deaths annually. The methodologies and technology being developed have immense potential for use with other cancers in the future.
In collaboration with experts from UCD and external support from IBM, Arctur will port the existing AI classification software to their secure data facility in Slovenia. The functionality of the AI technology will be confirmed, and new instances of the trained AI model will be implemented to be downloaded and installed on a laptop for use in the OR.
For more information visit CLASSICA website or follow CLASSICA on Twitter @classicaproject.
Other news
Arctur Launches BulevAR: A Web App Rewarding Visitors to GO! 2025 ECC
BulevAR, an interactive web application that enhances visitor engagement at the European Capital of Culture GO! 2025, developed by Arctur. The app encourages exploration, strengthens cross-border...
3. 2. 2025 / Industry, eHealth, Tourism, Heritage, GOV & NGOsAI Trends and Arctur's Involvement: Shaping the Future of Innovation
Artificial Intelligence (AI) is transforming industries globally, reshaping how we work, learn, and live. Arctur plays a role in this transformation by leveraging its expertise to create innovative...
21. 1. 2025 / HeritageReflecting on 2024 with Heritage+ : A Year of Innovation, Collaboration, and Cultural Connection
As 2024 ended, Heritage+ is taking a moment to reflect on the journey the year brought. It’s been a year filled with creativity, innovation, and a deep commitment to bringing cultural heritage closer...